Clinical outcomes and survival of advanced renal cancer patients in Phase I clinical trials.

被引：0
|
作者：
Malik, Laeeq [1 ]
Parsons, Helen [2 ]
Mahalingam, Devalingam [1 ]
Ehler, Benjamin [2 ]
Goros, Martin [2 ]
Brenner, Andrew [1 ]
Sarantopoulos, John [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-A70
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A70
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.
    Gyawali, Bishal
    Hwang, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: The NCCHE experience
    Kawazoe, Akihito
    Shitara, Kohei
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Yoshino, Takayuki
    Doi, Toshihiko
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [23] Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience
    Kawazoe, Akihito
    Shitara, Kohei
    Fukuoka, Shota
    Noguchi, Masaaki
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Fuse, Nozomu
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 664 - 670
  • [24] Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience
    Akihito Kawazoe
    Kohei Shitara
    Shota Fukuoka
    Masaaki Noguchi
    Yasutoshi Kuboki
    Hideaki Bando
    Wataru Okamoto
    Takashi Kojima
    Nozomu Fuse
    Takayuki Yoshino
    Atsushi Ohtsu
    Toshihiko Doi
    Investigational New Drugs, 2015, 33 : 664 - 670
  • [25] Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
    Papadatos-Pastos, Dionysis
    Roda, Desam
    Luken, Maria Jose De Miguel
    Petruckevitch, Ann
    Jalil, Awais
    Capelan, Marta
    Michalarea, Vasiliki
    Lima, Joao
    Diamantis, Nikolaos
    Bhosle, Jaishree
    Molife, L. Rhoda
    Banerji, Udai
    de Bono, Johann S.
    Popat, Sanjay
    O'Brien, Mary E. R.
    Yap, Timothy A.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 56 - 62
  • [26] Efficacy of immunotherapy agents in patients with metastatic breast cancer treated in phase I clinical trials.
    Kagihara, Jodi A.
    Weiss, Jennifer A.
    Nicklawsky, Andrew
    Gao, Dexiang
    Borges, Virginia F.
    Kabos, Peter
    Jimeno, Antonio
    Diamond, Jennifer R.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 69 - 70
  • [27] Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials.
    Nardo, Mirella
    Gouda, Mohamed Alaa
    Ahmed, Jibran
    Barreto, Carmelia Maria Noia
    Nelson, Blessie Elizabeth
    Araujo, Dejka M.
    Blumenschein, George R.
    Tsimberidou, Apostolia Maria
    Piha-Paul, Sarina A.
    Dumbrava, Ecaterina Elena
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Expanding rural access to phase I clinical trials.
    Powell, Steven Francis
    Bleeker, Jonathan
    Sumey, Christopher Joseph
    Vogel, Staci
    vanDonkersgoed, Sherra
    Atkins, Kristi
    Ellison, Christie
    Hove, Jenna
    Black, Lora Jane
    Waggoner, Jill
    Kelley, Jacqueline
    Bell, Maria C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Patterns of hepatic impairment in phase I clinical trials.
    Mansfield, Aaron Scott
    Vulih, Diana
    Smith, Gary L.
    Harris, Pamela Jo
    Ivy, S. Percy
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Analysis of proportion of geriatric patients in phase III cancer clinical trials.
    Gopishetty, Swathi
    Kota, Vamsi
    Guddati, Achuta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345